WW International, Inc. (WW) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite growth in clinical subscriptions and high ARPU, the 10% revenue decline and adjusted EBITDA loss are concerning. Positive impacts from new oral medications and a strong gross margin are offset by a decrease in cash reserves and a flat outlook for behavioral subscribers. The Q&A reveals strategic plans but lacks immediate catalysts for significant stock movement. Overall, mixed signals suggest a neutral stock reaction.
Key Financial Performance
Clinical subscription revenue Grew 32% year-over-year. This growth is attributed to the increasing demand for the Med+ tier and the launch of the Wegovy Pill.
End-of-period Clinical subscribers Grew 46% year-over-year. This growth reflects the success of the Med+ tier and the integration of clinical capabilities.
Core+ subscribers Increased to 537,000, representing a 6% year-over-year growth. This growth is driven by enhanced virtual workshop experiences and tailored programs like GLP-1 success and menopause programs.
Virtual workshop attendance among Core+ members Increased nearly 40% year-over-year. This increase is due to the expansion of virtual workshop experiences and tailored sessions.
ARPU (Average Revenue Per User) Increased 13% year-over-year to $20.59. This increase is driven by the shift of members to higher-value tiers like Core+ and Med+.
Revenue $168 million, down 10% year-over-year. The decline is due to subscriber dynamics between subscription tiers, with a 32% growth in Clinical subscription revenue but a 17% decline in Behavioral subscription revenue.
Adjusted gross margin 73.6%, near record highs. This is despite the mix shift towards Clinical, achieved through structural actions and operational efficiencies.
Marketing expense $93 million, reflecting front-loaded investment to drive awareness of the Med+ positioning and the Wegovy Pill launch.
Adjusted EBITDA Loss of $1.8 million. This is attributed to peak marketing investments and other operational costs.
Cash and cash equivalents $121 million at the end of Q1, down from $160 million at the end of Q4. The decrease is due to adjusted EBITDA loss, interest payments, capital expenditures, and marketing payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GLP-1 Integration: WeightWatchers is integrating GLP-1 medications with its behavioral and community programming to improve health outcomes and drive long-term growth.
Med+ Tier: The Med+ membership tier, which includes clinical capabilities, grew 32% in revenue and 46% in subscribers year-over-year.
Core+ Tier: Core+ subscribers grew 6% year-over-year to 537,000, with increased engagement in virtual workshops and tailored programs.
GLP-1 Market Expansion: The launch of oral GLP-1 medications has expanded the total addressable market, with WeightWatchers increasing access to FDA-approved medications.
Operational Efficiencies: Gross margin remains near record highs at 73.6%, supported by structural cost actions and improved margin profiles in both Behavioral and Clinical segments.
Marketing Investments: $93 million was invested in Q1 marketing to drive awareness of the Med+ tier and capitalize on the Wegovy Pill launch.
Strategic Transformation: WeightWatchers is undergoing a multiyear transformation to align its legacy business with market realities and focus on sustainable growth.
Debt Reduction: The company plans to utilize $37 million in cash to reduce its term loan principal by $42 million, lowering annual interest expenses by $4 million.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Behavioral Business Headwinds: The Behavioral business continues to face challenges, including a 25% year-over-year decline in Behavioral subscribers and incremental pressure due to strategic prioritization of the Med+ tier. This reflects ongoing secular headwinds and market shifts.
Marketing Spend Allocation: The company has strategically front-loaded marketing expenses to drive awareness of the Med+ tier, which may lead to short-term financial strain and lower returns on investment if not effectively managed.
Debt and Interest Costs: The company faces significant debt obligations, including a term loan with a 10.5% interest rate. While steps are being taken to reduce debt, interest expenses remain a financial burden, impacting cash flow and profitability.
Clinical Business Costs: The Clinical business, while growing, carries higher costs of service due to clinician staffing. This could pressure margins despite efforts to improve operational efficiencies.
Subscriber Dynamics: The shift from Core to higher-value tiers like Core+ and Med+ is positive for ARPU but reflects a decline in the lower-tier subscriber base, which could impact overall revenue stability.
Economic and Market Risks: The company operates in a rapidly evolving weight health industry, with increasing competition and scrutiny on compounded medications. These factors could impact market share and growth potential.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company reaffirms its 2026 revenue guidance of $620 million to $635 million.
Adjusted EBITDA Guidance: The company reaffirms its 2026 adjusted EBITDA guidance of $105 million to $115 million.
Clinical Subscriber Growth: Sequential Clinical subscriber growth is expected in the remaining quarters of 2026, though at a lower rate than Q1 due to seasonal normalization and reduced marketing spend.
Clinical Subscription Revenue: Clinical subscription revenue is projected to grow to approximately 25% to 30% of 2026 revenue, up from 16% in 2025.
Core+ Subscriber Growth: The company expects to grow Core+ subscribers in 2026.
Gross Margin: Gross margin is expected to remain above 72% in 2026, with modest declines compared to 2025 due to scaling of the Clinical business.
Marketing Expense: Marketing expense as a percentage of revenue is expected to increase modestly in 2026 compared to 2025.
Product Development Expense: Quarterly product development expenses are expected to remain at a similar run rate as Q1 2026.
SG&A Expense: Modest savings in SG&A expenses are expected in 2026, driven by the exit from the corporate headquarters lease and operational discipline.
Cash Generation: The company expects to generate cash through the remainder of 2026, with key drivers being adjusted EBITDA, interest, CapEx, and cash taxes.
Interest Costs: Interest costs are expected to be approximately $45 million to $50 million in 2026, reflecting lower quarterly interest following debt repayments.
Capital Expenditures: Quarterly capital expenditures are expected to remain at a similar run rate as Q1 2026.
Cash Taxes: Cash taxes for 2026 are expected to be between $5 million and $10 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you help us think through the shape of both Behavioral and Clinical subscriber growth through the year, especially as marketing mixes back to a bit more of a balance between segments?
A:The company expects Behavioral subscriber numbers to remain fairly flat due to a balance between Core+ and Core offerings and recalibrated marketing. Clinical subscriber growth is anticipated to be sequential but significantly muted compared to Q4 2025 to Q1 2026. Clinical revenue is expected to grow significantly, contributing 25%-30% of total revenue.
Q:How has the launch of new oral medications impacted the funnel from top of funnel interest to conversion, and what is the importance of the oral category in 1Q?
A:The launch of new oral medications has positively impacted the business by increasing access and affordability, aiding both top-of-funnel interest and patient retention. The company views these medications as an opportunity to enhance its offerings and maintain a competitive advantage. Real-world data shows a 19.4% weight loss at 12 months, which is higher than competitors.
Q:What are your thoughts on additional voluntary paydowns of the term loan given its current trading position?
A:The company is continuously managing its debt and equity profile. While Q1 2026 was a cash-use quarter, cash accretion is expected from Q2 to Q4. The company will monitor opportunities for debt reduction while balancing business investments.
Q:What is driving the growth in the Core+ offering, and how sustainable is this momentum?
A:Growth in Core+ is driven by new virtual experiences, workshops led by RDs and physicians, new coach creators, and medically-centric programs like menopause and GLP-1 success. The Core+ offering has a 2x ARPU compared to Core subscribers, and the company sees potential for sustained growth.
Q:What is the impact of compounded semaglutide on Clinical revenue and subscriber growth, and how will this evolve throughout the year?
A:The compounded semaglutide offering, discontinued in May 2025, created a $20 million headwind and a churn event in Q3 2025. About 20% of those members were retained. Revenue growth will benefit from easing comps in Q3 and Q4 2026, though subscriber count growth may not align directly with revenue growth.
Q:Can you provide more details on the shift in brand strategy or marketing and its appeal to different demographics?
A:The company focused on modernizing its brand and increasing awareness of its Clinical business and Med+ offering. A 10-point increase in awareness of the GLP-1 offering and 50% of new Clinical members being new to WeightWatchers were achieved. Future advertising will cover the broader portfolio, not just Med+.
Q:What is the size and contribution of the menopause program to overall results?
A:The menopause program, part of the Core+ SKU, has contributed to the growth of the Core+ subscriber base in Q1 2026. It is a key factor in the first growth of Core+ in years.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided sufficient detail and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARPU offering
ARPU tier
COO Interim
Clinical ARPU
Commission today
Core ARPU
Core GLP
Core member
Core subscriber
Core tier
Executive COO
GLP era
GLP leader
GLP success
Interim Principal
Med tier
Members workshop
Officer member
WeightWatchers Conference
advance
body
capability
ecosystem
evidence
industry
intersection
letter press
lifetime value
menopause
portfolio
programming
return
shareholder letter
value membership
version
weight health
win
WW Transcript
WW International, Inc. (WW) Q1 2026 Earnings Call Transcript
Unknown5-11
Despite growth in clinical subscriptions and high ARPU, the 10% revenue decline and adjusted EBITDA loss are concerning. Positive impacts from new oral medications and a strong gross margin are offset by a decrease in cash reserves and a flat outlook for behavioral subscribers. The Q&A reveals strategic plans but lacks immediate catalysts for significant stock movement. Overall, mixed signals suggest a neutral stock reaction.
WW International, Inc. (WGHTQ) Q4 2025 Earnings Call Transcript
Unknown3-16
The earnings call highlights mixed results: strong clinical subscriber growth and increased ARPU, but a decline in behavioral subscribers and total revenue. Management's optimistic outlook on demand for new products and demographic expansion is positive, but lack of specific guidance and declining cash reserves pose concerns. The Q&A reveals positive sentiment towards new member growth and partnerships, yet vague responses on financial projections create uncertainty. Overall, the mixed signals and cautious market sentiment suggest a neutral stock price movement.
WW International, Inc. (WW) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. While clinical subscriber growth and strategic partnerships, including one with Amazon, are positive, the decline in revenue and behavioral subscribers is concerning. The company's financial health appears stable, with a significant reduction in term loan and cash reserves increase. However, uncertainties in the clinical business and lack of specific guidance on influencer campaign returns temper optimism. The market may react cautiously, resulting in a neutral stock price movement over the next two weeks.
WW International, Inc. (WW) Q2 2025 Earnings Call Transcript
Unknown8-11
The earnings call reveals several concerning factors: declining total subscribers, revenue headwinds, and challenges in transitioning Clinical members away from compounded semaglutide. Despite some positive financial metrics, such as debt reduction and ARPU growth, the overall sentiment is negative due to revenue decline, subscriber loss, and lack of clear guidance on future strategies. The Q&A section highlights competitive pressures and the absence of detailed plans for addressing challenges, further contributing to the negative outlook.
WW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
